Shares Issued
As at 11 July 2025, the number of shares in issue was 113,656,253. The Company does not hold any ordinary shares in treasury.
Significant Shareholders
At 11July 2025, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
Shareholder | No. of ordinary shares | % of issued share capital |
---|---|---|
Canaccord Genuity Group Inc | 8,066,263 | 7.10% |
Rathbone Investment Management Ltd | 7,467,753 | 6.57% |
Unicorn AIM VCT plc | 6,397,290 | 5.63% |
Maven Capital Partners UK LLP | 4,716,463 | 4.15% |
Director Shareholdings
Director | No. of ordinary shares | % of issued share capital |
---|---|---|
Colin James Walsh 2 | 3,379,001 2 | 2.97% |
Dr Simon Gordon Douglas | 1,061,062 1 | 0.93% |
Dr Richard John Buick | 1,000,000 | 0.88% |
Dr Adrian Kinkaid | 850,000 | 0.75% |
Dr Matthew Baker | 292,902 | 0.26% |
Stephen Smyth | - | 0.00% |
1 Excludes Ordinary Shares held by relatives of Simon Douglas
2Includes 1,204,883 Ordinary Shares held by Walsh Strategic Management Limited and 211,618 Ordinary Shares held by Crescent Capital III GP Limited, companies controlled by Colin Walsh. It also includes 1,400,000 Ordinary Shares held by HamNiv (GP) Limited, a subsidiary of Crescent Capital NI Limited ("Crescent Capital"). Colin Walsh is the Chief Executive and founder of Crescent Capital.
Shares not in public hands
Insofar as it is aware, as at 11 July 2025, 5.79% of the Company's securities is not in public hands.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Restrictions in transfer of AIM securities
There are no restrictions on the transfer of the Company's ordinary shares.
UK City Code on Takeovers and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Other exchanges and trading platforms
Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Shareholder Circulars
Page last updated: 11 July 2025